Pipeline of Multiple Sclerosis Market H2 2015 Review Research

ReportsnReports adds Multiple Sclerosis Market research to its database.

Pune, India – March 7, 2016 /MarketersMedia/ —

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Get discount on this research report at http://www.reportsnreports.com/contacts/Discount.aspx?name=468276 .

Companies discussed in this research report at 4D Pharma Plc, 4SC AG, AB Science SA, AbbVie Inc., Ablynx NV, Acorda Therapeutics, Inc., Actelion Ltd, Addex Therapeutics Ltd, Aegera Therapeutics Inc., Aegis Therapeutics, LLC, Affectis Pharmaceuticals AG, AiCuris GmbH & Co. KG, Alkermes Plc, Allozyne, Inc., Amarna Therapeutics B.V., Antipodean Pharmaceuticals, Inc., Antisense Therapeutics Limited, Antitope Limited, Aphios Corporation, Apitope International NV, Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Array BioPharma Inc., Arrien Pharmaceuticals, LLC, Artielle ImmunoTherapeutics, Inc., Athersys, Inc., Axxam SpA, Baliopharm AG, Bio-Cancer Treatment International Limited, BIOCAD, Biocon Limited, Biogen, Inc., Biogenomics Limited, Biokine Therapeutics Ltd., Biomar Microbial Technologies, Bionature E.A. Ltd., Bioncotech Therapeutics S.L., Bionovis SA, Bionure Farma, S.L., Biovista Inc., Bird Rock Bio, Inc., Biscayne Pharmaceuticals, Inc., Bolder Biotechnology, Inc., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, C4X Discovery Limited, Caladrius Biosciences, Inc., CASI Pharmaceuticals Inc., Catalyst Pharmaceutical Partners, Inc., Cell Cure Neurosciences, Ltd., Cell2B S.A., Cellceutix Corporation, Chong Kun Dang Pharmaceutical Corp., Cognosci, Inc., Commence Bio, Inc., Compugen Ltd., Connexios Life Sciences Pvt. Ltd., Critical Outcome Technologies Inc., Daval International Limited, Deltanoid Pharmaceuticals Inc., Digna Biotech, S.L., Dimerix Bioscience Pty Ltd, Dong-A Socio Group, Effimune SAS, Eisai Co., Ltd., Endece, LLC, Evgen Pharma PLC, Evotec AG, F. Hoffmann-La Roche Ltd., Forward Pharma A/S, Genervon Biopharmaceuticals, LLC, GeNeuro SA, Genmab A/S, Genzyme Corporation, GlaxoSmithKline Plc, GliaCure Inc., Glialogix, Inc., Hansa Medical AB, Hanwha Chemical Corporation, Harbor Therapeutics, Inc. and Hutchison MediPharma Limited.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete research report of 922 pages with TOC is available at http://www.reportsnreports.com/reports/468276-multiple-sclerosis-pipeline-review-h2-2015.html .

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For more information about us, please visit http://www.reportsnreports.com/

Contact Info:
Name: Ritesh Tiwari
Organization: ReportsandReports
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41

Source: http://marketersmedia.com/pipeline-of-multiple-sclerosis-market-h2-2015-review-research/105963

Release ID: 105963